Why the study?
Does drug-eluting stenting improve MACCE compared to bypass surgery in patients with left main coronary disease with and without diabetes mellitus?
Does drug-eluting stenting improve MACCE compared to bypass surgery in patients with left main coronary disease with and without diabetes mellitus?
In a 10-year extended follow-up, DES and CABG showed no significant difference in MACCE or mortality for left main coronary disease, regardless of diabetes status, though TVR was higher with DES.
Answers are grounded in this paper and cite their sources.
No long-term MACCE or mortality difference between DES and CABG in left main disease by diabetes status; confirms prior results but underscores higher TVR with stenting.
-for-interaction=0.48). There were no significant between-group differences in composite of death, MI, or stroke, and all-cause mortality, regardless of DM status. TVR rates were consistently higher after DES than CABG. Conclusions In this 10-year extended follow-up of PRECOMBAT, we found no significant difference between DES and CABG with respect to the incidences of MACCE, serious composite outcome, and all-cause mortality in patients with and without DM with LMCA disease. However, owing to the limited number of patients and no adjustment for multiple testing, overall findings should be considered hypothesis-generating, highlighting the need for further research. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03871127 and NCT00422968.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: